Compare SMBC & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SMBC | AMPH |
|---|---|---|
| Founded | 1887 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 819.7M | 971.8M |
| IPO Year | 2011 | 2005 |
| Metric | SMBC | AMPH |
|---|---|---|
| Price | $76.75 | $21.78 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $69.50 | $28.38 |
| AVG Volume (30 Days) | 106.9K | ★ 614.5K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.59 | 0.14 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | $16.09 | $6.90 |
| Revenue Next Year | $5.69 | $4.64 |
| P/E Ratio | ★ $16.29 | $150.29 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $47.60 | $16.65 |
| 52 Week High | $75.50 | $31.26 |
| Indicator | SMBC | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 71.13 | 61.84 |
| Support Level | $66.74 | $16.84 |
| Resistance Level | N/A | $24.61 |
| Average True Range (ATR) | 1.74 | 0.85 |
| MACD | 0.34 | 0.24 |
| Stochastic Oscillator | 82.42 | 85.85 |
Southern Missouri Bancorp Inc is a USA-based holding company for Southern Missouri Savings Bank. The principal business of the bank consists of attracting retail deposits from the general public and using such deposits along with wholesale funding from the Federal Home Loan Bank of Des Moines, and to a lesser extent, brokered deposits, to invest in one- to four-family residential mortgage loans, mortgage loans secured by commercial real estate, commercial non-mortgage business loans, and consumer loans. It is engaged in providing the range of banking and financial services to individuals and corporate customers in its market areas. The company derives revenue principally from interest earned on loans, debt securities, bank card interchange fees, loan late charges and another fee income.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.